BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 15005736)

  • 1. A double-blind, placebo-controlled birch allergy vaccination study: inhibition of CD23-mediated serum-immunoglobulin E-facilitated allergen presentation.
    van Neerven RJ; Arvidsson M; Ipsen H; Sparholt SH; Rak S; Würtzen PA
    Clin Exp Allergy; 2004 Mar; 34(3):420-8. PubMed ID: 15005736
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Blocking antibodies induced by specific allergy vaccination prevent the activation of CD4+ T cells by inhibiting serum-IgE-facilitated allergen presentation.
    van Neerven RJ; Wikborg T; Lund G; Jacobsen B; Brinch-Nielsen A; Arnved J; Ipsen H
    J Immunol; 1999 Sep; 163(5):2944-52. PubMed ID: 10453043
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A double-blind placebo-controlled birch allergy vaccination study II: correlation between inhibition of IgE binding, histamine release and facilitated allergen presentation.
    Würtzen PA; Lund G; Lund K; Arvidsson M; Rak S; Ipsen H
    Clin Exp Allergy; 2008 Aug; 38(8):1290-301. PubMed ID: 18510696
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vaccination for birch pollen allergy. Induction of affinity-matured or blocking IgG antibodies does not account for the reduced binding of IgE to Bet v 1.
    Svenson M; Jacobi HH; Bødtger U; Poulsen LK; Rieneck K; Bendtzen K
    Mol Immunol; 2003 Jan; 39(10):603-12. PubMed ID: 12431394
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Kinetics, cross-reactivity, and specificity of Bet v 1-specific IgG4 antibodies induced by immunotherapy with birch pollen.
    Subbarayal B; Schiller D; Möbs C; de Jong NW; Ebner C; Reider N; Bartel D; Lidholm J; Pfützner W; Gerth van Wijk R; Vieths S; Bohle B
    Allergy; 2013 Nov; 68(11):1377-86. PubMed ID: 24053565
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Birch pollen immunotherapy results in long-term loss of Bet v 1-specific TH2 responses, transient TR1 activation, and synthesis of IgE-blocking antibodies.
    Möbs C; Ipsen H; Mayer L; Slotosch C; Petersen A; Würtzen PA; Hertl M; Pfützner W
    J Allergy Clin Immunol; 2012 Nov; 130(5):1108-1116.e6. PubMed ID: 23021882
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Allergen-specific IgE levels and the ability of IgE-allergen complexes to cross-link determine the extent of CD23-mediated T-cell activation.
    Villazala-Merino S; Rodriguez-Dominguez A; Stanek V; Campion NJ; Gattinger P; Hofer G; Froeschl R; Fae I; Lupinek C; Vrtala S; Breiteneder H; Keller W; Perkmann T; Nakamura R; Pickl WF; Valenta R; Eckl-Dorna J; Niederberger V
    J Allergy Clin Immunol; 2020 Mar; 145(3):958-967.e5. PubMed ID: 31775017
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of CD23-dependent facilitated allergen binding to B cells following vaccination with genetically modified hypoallergenic Bet v 1 molecules.
    Pree I; Shamji MH; Kimber I; Valenta R; Durham SR; Niederberger V
    Clin Exp Allergy; 2010 Sep; 40(9):1346-52. PubMed ID: 20604801
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A nonallergenic birch pollen allergy vaccine consisting of hepatitis PreS-fused Bet v 1 peptides focuses blocking IgG toward IgE epitopes and shifts immune responses to a tolerogenic and Th1 phenotype.
    Marth K; Breyer I; Focke-Tejkl M; Blatt K; Shamji MH; Layhadi J; Gieras A; Swoboda I; Zafred D; Keller W; Valent P; Durham SR; Valenta R
    J Immunol; 2013 Apr; 190(7):3068-78. PubMed ID: 23440415
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    Aglas L; Bethanis A; Chrusciel P; Stolz F; Gruen M; Jaakkola UM; Jongejan L; Yatkin E; Van Ree R
    Front Immunol; 2020; 11():2118. PubMed ID: 33013894
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detection of specific IgE antibodies in sera of Japanese birch-allergic patients using recombinant allergens Bet v 1, Bet v 2 and Bet v 4.
    Shirasaki H; Yamamoto T; Koyanagi Y; Watanabe N; Himi T
    Allergol Int; 2008 Mar; 57(1):93-6. PubMed ID: 18209509
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High correlation of specific IgE sensitization between birch pollen, soy and apple allergens indicates pollen-food allergy syndrome among birch pollen allergic patients in northern China.
    Hao GD; Zheng YW; Wang ZX; Kong XA; Song ZJ; Lai XX; Spangfort MD
    J Zhejiang Univ Sci B; 2016 May; 17(5):399-404. PubMed ID: 27143268
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD23 surface density on B cells is associated with IgE levels and determines IgE-facilitated allergen uptake, as well as activation of allergen-specific T cells.
    Selb R; Eckl-Dorna J; Neunkirchner A; Schmetterer K; Marth K; Gamper J; Jahn-Schmid B; Pickl WF; Valenta R; Niederberger V
    J Allergy Clin Immunol; 2017 Jan; 139(1):290-299.e4. PubMed ID: 27372566
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunotherapy with a modified birch pollen extract in allergic rhinoconjunctivitis: clinical and immunological effects.
    Ceuppens JL; Bullens D; Kleinjans H; van der Werf J;
    Clin Exp Allergy; 2009 Dec; 39(12):1903-9. PubMed ID: 20085600
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BASALIT trial: double-blind placebo-controlled allergen immunotherapy with rBet v 1-FV in birch-related soya allergy.
    Treudler R; Franke A; Schmiedeknecht A; Ballmer-Weber B; Worm M; Werfel T; Jappe U; Biedermann T; Schmitt J; Brehler R; Kleinheinz A; Kleine-Tebbe J; Brüning H; Ruëff F; Ring J; Saloga J; Schäkel K; Holzhauser T; Vieths S; Simon JC
    Allergy; 2017 Aug; 72(8):1243-1253. PubMed ID: 27998002
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of 2 months of allergen-specific immunotherapy with Bet v 1-derived contiguous overlapping peptides in patients with allergic rhinoconjunctivitis: Results of a phase IIb study.
    Spertini F; DellaCorte G; Kettner A; de Blay F; Jacobsen L; Jutel M; Worm M; Charlon V; Reymond C
    J Allergy Clin Immunol; 2016 Jul; 138(1):162-8. PubMed ID: 27373329
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum-IgE-facilitated allergen presentation in atopic disease.
    van der Heijden FL; Joost van Neerven RJ; van Katwijk M; Bos JD; Kapsenberg ML
    J Immunol; 1993 Apr; 150(8 Pt 1):3643-50. PubMed ID: 8468493
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Birch pollen immunotherapy leads to differential induction of regulatory T cells and delayed helper T cell immune deviation.
    Möbs C; Slotosch C; Löffler H; Jakob T; Hertl M; Pfützner W
    J Immunol; 2010 Feb; 184(4):2194-203. PubMed ID: 20048125
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Filling the Antibody Pipeline in Allergy: PIPE Cloning of IgE, IgG
    Köhler VK; Crescioli S; Fazekas-Singer J; Bax HJ; Hofer G; Pranger CL; Hufnagl K; Bianchini R; Flicker S; Keller W; Karagiannis SN; Jensen-Jarolim E
    Int J Mol Sci; 2020 Aug; 21(16):. PubMed ID: 32784509
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunological comparison of allergen immunotherapy tablet treatment and subcutaneous immunotherapy against grass allergy.
    Aasbjerg K; Backer V; Lund G; Holm J; Nielsen NC; Holse M; Wagtmann VR; Würtzen PA
    Clin Exp Allergy; 2014 Mar; 44(3):417-28. PubMed ID: 24734285
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.